The FDA has said it will revisit decisions as new data becomes available
These publications are smaller in scope than our Special Health Reports, but they are written in the same clear, easy-to-understand language, and they provide the authoritative health advice you expect from Harvard Health Publishing
If youre not seeing results, its typically because youre not on a high enough dosage due to tolerability issues or because the dosage hasnt been increased adequately
The rate of acute pancreatitis was 0.4% higher among GLP-1 users, in year one, which translates to one additional case for every 250 GLP-1 users
There is no scenario where stacking two GLP-1 agonists makes pharmacological sense, and no calculator can make an unsafe combination safe
A dozen India companies have launched generic semaglutide over the last three weeks, with roughly 70-90% discounted to the innovators price when patent was in force Price Disruption Novo sells the drug under brand names Wegovy (anti-obesity) and Ozempic (anti-diabetic)